使用丁丙诺啡治疗新生儿戒断综合征：一项质量改进研究。
Using buprenorphine to treat neonatal abstinence syndrome: a quality improvement study.
机构信息
Wake Forest University Baptist Medical Center, Brenner Children's Hospital, Winston-Salem, NC, USA.
Novant Health Forsyth Medical Center, Winston-Salem, NC, USA.
出版信息
J Perinatol. 2021 Jun;41(6):1480-1486. doi: 10.1038/s41372-021-01035-4. Epub 2021 Mar 23.
OBJECTIVE
To assess if treating neonatal abstinence syndrome (NAS) with sublingual buprenorphine (SLB) would decrease the mean duration of therapy (DOT) and length of birth hospital stay (LOS).
STUDY DESIGN
Conducted at a tertiary hospital with >6000 annual deliveries and a 2% incidence of NAS, a quality improvement study using plan-do-study-act (PDSA) cycles were utilized. Outcomes were measured using statistical process control (SPC) charts.
RESULTS
All NAS patients were treated with SLB, no adverse reactions were reported and the need for an adjunctive agent was static. SPC charts demonstrated decreased variability and special cause variation indicating a reduction in both DOT (from 14.5 to 8.5 days) and LOS (from 18.5 to 13 days).
目的
评估舌下美沙酮（SLB）治疗新生儿戒断综合征（NAS）是否会缩短平均治疗持续时间（DOT）和分娩住院时间（LOS）。
研究设计
在一家每年有超过 6000 次分娩和 2% NAS 发生率的三级医院进行，使用计划-执行-研究-行动（PDSA）循环进行质量改进研究。使用统计过程控制（SPC）图表来衡量结果。
结果
所有 NAS 患者均接受 SLB 治疗，未报告不良反应，且无需辅助药物。SPC 图表显示变异性和特殊原因变异减少，表明 DOT（从 14.5 天减少到 8.5 天）和 LOS（从 18.5 天减少到 13 天）均减少。
Zotero 插件